Novartis Korea Venture Fund invest $6 million to local biotech company

Published: 2009-09-21 06:58:00

Updated: 2009-09-21 06:58:00

PharmAbcine, a specialized biotech company focused on the development of fully-human monoclonal antibodies for the treatment of cancer and inflammatory diseases, said on September 16 that it has received $6 million in a Series A financing for the next three years from Novartis Korea Venture Fund and OrbiMed's Caduceus Asia Partners.

The two financing venture firms led the investment with add...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.